SIRPA and neoplasm: To this end, a bispecific antibody targeting PD-L1 on tumor cells and SIRPα on APCs was shown to produce enhanced cytotoxicity to murine colon cancer cells when compared with either anti-PD-L1 or anti-SIRPα monotherapy alone [368].